Guideline-Recommended Treatments for HER2-Negative Metastatic Breast Cancer

Treatment for HER2-negative metastatic breast cancer depends on factors like hormone receptor status, with chemo/immunotherapy for PD-L1-positive triple negative disease, PARP inhibitors for BRCA mutations, and antibody-drug conjugates as options after first line therapy.

EP: 1.The Role of the HER2 Receptor in Breast Cancer

EP: 2.Necessary Tests After a Diagnosis of Breast Cancer

EP: 3.Factors Informing Individualized Treatment Decision-Making for HER2-Positive Metastatic Breast Cancer

EP: 4.Discussing Clinical Trial Enrollment for HER2-Positive Metastatic Breast Cancer With Your Oncologist

EP: 5.Guideline-Recommended Treatments for HER2-Positive Metastatic Breast Cancer

Now Viewing

EP: 6.Guideline-Recommended Treatments for HER2-Negative Metastatic Breast Cancer

EP: 7.Guideline-Recommended Treatments for HER2-Low Metastatic Breast Cancer

EP: 8.How HER2 Targeted Therapies Fight HER2-Positive Metastatic Breast Cancer

EP: 9.Imaging Scans for Assessing HER2-Positive Breast Cancer Progression and Treatment Response

EP: 10.Potential Severe Side Effects of HER2-Positive Metastatic Breast Cancer Treatment

EP: 11.Collaborating With Your Oncology Care Team to Manage Side Effects of HER2-Positive Metastatic Breast Cancer Treatment

Related Videos

Related Content

Advertisement

April 29th 2025

A Fellow Cancer Survivor Gives Me a Useful Message

Laura Yeager

A chance meeting with my childhood friend reminded me — and others— that living with cancer means taking things one day at a time.

February 5th 2024

FDA, Cancer Vaccine Updates and a Misguiding of Breast Cancer Treatment

Alex Biese Brielle Benyon

One cancer vaccine may still be years away from being available, a breast cancer test may be misguiding treatments for Black women and the review of two oncology regimens are being expedited by the FDA.

April 28th 2025

How Mammogram Reminders Can Be More Thoughtful Following Breast Cancer

Felicia Mitchell

I reflect on how a generic mammogram reminder overlooked my experience as a breast cancer survivor and how thoughtful messaging could make a difference.

December 12th 2023

Conference Highlights from SABCS

Alex Biese Brielle Benyon

CURE® recently covered the San Antonio Breast Cancer Symposium. In case you missed it, here is some news that came out of the conference that patients should know about.

April 21st 2025

Enhertu Combo Improves Progression in HER2+ Metastatic Breast Cancer

Ryan Scott

Enhertu plus Perjeta demonstrated improvement in progression-free survival versus standard treatment in HER2-positive metastatic breast cancer.

April 21st 2025

Trodelvy Plus Keytruda May Slow Progression in mTNBC

Alex Biese

In some patients with advanced triple-negative breast cancer, Trodelvy plus Keytruda was associated with an improvement in disease progression.

Related Content

Advertisement

April 29th 2025

A Fellow Cancer Survivor Gives Me a Useful Message

Laura Yeager

A chance meeting with my childhood friend reminded me — and others— that living with cancer means taking things one day at a time.

February 5th 2024

FDA, Cancer Vaccine Updates and a Misguiding of Breast Cancer Treatment

Alex Biese Brielle Benyon

One cancer vaccine may still be years away from being available, a breast cancer test may be misguiding treatments for Black women and the review of two oncology regimens are being expedited by the FDA.

April 28th 2025

How Mammogram Reminders Can Be More Thoughtful Following Breast Cancer

Felicia Mitchell

I reflect on how a generic mammogram reminder overlooked my experience as a breast cancer survivor and how thoughtful messaging could make a difference.

December 12th 2023

Conference Highlights from SABCS

Alex Biese Brielle Benyon

CURE® recently covered the San Antonio Breast Cancer Symposium. In case you missed it, here is some news that came out of the conference that patients should know about.

April 21st 2025

Enhertu Combo Improves Progression in HER2+ Metastatic Breast Cancer

Ryan Scott

Enhertu plus Perjeta demonstrated improvement in progression-free survival versus standard treatment in HER2-positive metastatic breast cancer.

April 21st 2025

Trodelvy Plus Keytruda May Slow Progression in mTNBC

Alex Biese

In some patients with advanced triple-negative breast cancer, Trodelvy plus Keytruda was associated with an improvement in disease progression.